MAIA | Ticker Profile - Titan Protect

MAIA

MAIA Biotechnology, Inc.

Healthcare · Biotechnology · ASE

$1.36

Data: 2026-05-14

✗ ETHICAL FAIL

WEAK MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$78M

Total market value of the company

Trailing P/E

0.00

Forward P/E

0.48

Based on estimated future earnings — lower means cheaper

Rev Growth

0.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-148.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.14

+792% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

https://maiabiotech.com

Country: United States Employees: 13 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PASS

Debt must be below 33% of total assets

Cash Ratio

43.9% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$40.50

What our model estimates this business is worth per share

Margin of Safety

96.6%

Deep discount to fair value — significant undervaluation

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

60.8th

Ranks in the top 39% of our 13,571 screened universe

Ethical Score

10.0

Valuation Score

95.0

Quality Score

20.0

Combined

43.0

Trading at $1 against a fair value of $40, a 97% discount. Fails ethical screen (Cash ratio). Ranks better than 71% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

-0.199

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0800

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.523

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-43.4%

Historical annualised return based on price data

Max Drawdown

-82.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$3.19

57% below the year high

52W Low

$0.87

56% above the year low

Avg Volume

870,585

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

5.6%

Moderate short interest

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.68

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

5.59

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.44

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-12,128,248

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-24,248,564

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$14.00

Target Median

$12.14

Target Low

$10.27

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2025-12-22	LOUIE NGAR YEE	Director	81,699	$100,000
2025-12-22	CHAOUKI STEVEN M	Director	40,849	$49,999
2025-12-22	SMITH STAN V	Director	57,189	$69,999
2025-12-05	SMITH STAN V	Director	13,740	$16,441
2025-11-28	VITOC VLAD	Chief Executive Officer	72,000	$79,849
2025-11-28	VITOC VLAD	Chief Executive Officer	72,000	$79,849
2025-11-28	LUPUT CRISTIAN	Director	38,145	$41,846
2025-11-26	SMITH STAN V	Director	15,000	$15,582
2025-11-25	VITOC VLAD	Chief Executive Officer	10,500	$10,144
2025-11-25	VITOC VLAD	Chief Executive Officer	10,500	$10,144

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Before you go